Physician profile
Kevin Wang
NPI 1497215966
$1,089.52
in general payments reported to CMS, 2019-2025
13 companies · $575 in 2025
The $575 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $273 · 2024: $241 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692 · Travel and Lodging: $258 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $691.75 |
| Travel and Lodging | $257.79 |
| Education | $139.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $257.79 | 2025 | Fitbone |
| Seagen INC. | $194.99 | 2023 | Adcetris |
| Astrazeneca Pharmaceuticals LP | $168.83 | 2025 | Datroway, Calquence |
| Genzyme Corporation | $128.26 | 2024 | |
| Incyte Corporation | $97.26 | 2023-2025 | Monjuvi, Zynyz |
| Pfizer INC. | $69.99 | 2024 | |
| Amgen INC. | $42.94 | 2024 | Lumakras |
| Inspire Medical Systems, INC. | $30.96 | 2025 | Inspire |
| Genmab U.S., INC. | $21.71 | 2025 | Epkinly |
| Glaxosmithkline, LLC. | $19.94 | 2025 | Ojjaara |
| Genentech USA, INC. | $19.82 | 2025 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $18.93 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.